3-150915034ZJX-lp
Living With CFNews & EventsTreatments

New cystic fibrosis drug has high potential, high cost

Written by Tracey Walker Source: Managed Healthcare Executive FDA’s approval of Vertex Pharmaceutical’s groundbreaking lumacaftor/ivacaftor (Orkambi) for cystic fibrosis (CF) is the first drug to treat the underlying cause of CF in people ages 12 and older with two copies of the F508del mutation. CF is an inherited chronic disease that affects …

READ MORE →
lauren_brenneman-702x375
Exercisefeatured_memberLiving With CFVideo

Lauren Brenneman – Hartford Hospital cystic fibrosis case study

CysticFibrosis.com welcomes Lauren Brenneman (LouLou) to the CysticFibrosis.com team. Lauren will help to carve out strategic paths as we move forward and serve the CF community. She will also be involved on many video productions we have planned in 2015. This is Lauren’s latest video and as you can see she …

READ MORE →
24h4 (468x312)
AdheranceExerciseLiving With CFTechnology

CF Innovators: Blown Away

An app aimed at helping younger people with cystic fibrosis stick to their exercise regime, and a cuddly bear to help children take control of their self-management were joint winners in a 24-hour Inclusive Design Challenge on Monday, which marked the launch of Sheffield Hallam University’s Design4Health conference. The challenge …

READ MORE →
shutterstock_156419843-770x470
Living With CFResearchRespiratory DiseaseTreatments

Concert Pharma’s Modified Version of Cystic Fibrosis Therapy Ivacaftor Outperforms Kalydeco in Early Testing

Written by Patricia Inacio, PhD Source: Cystic Fibrosis News Today Concert Pharma recently announced successful results from a Phase 1 single ascending dose clinical trial for their lead investigational drug CTP-656 as a therapy for cystic fibrosis. Cystic fibrosis is a life-threatening disease characterized by a progressive lung function decline and is caused …

READ MORE →